IFP Advisors, Inc - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 116 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.

Quarter-by-quarter ownership
IFP Advisors, Inc ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q4 2022$1
-99.9%
80.0%0.00%
Q3 2022$1,0000.0%80.0%0.00%
Q2 2022$1,0000.0%80.0%0.00%
Q1 2022$1,000
-96.4%
8
-99.9%
0.00%
-100.0%
Q3 2021$28,000
+211.1%
11,077
+260.0%
0.00%
Q2 2021$9,000
+12.5%
3,0770.0%0.00%
Q1 2021$8,000
+300.0%
3,077
+185.7%
0.00%
Q4 2020$2,000
+100.0%
1,0770.0%0.00%
Q3 2020$1,0000.0%1,0770.0%0.00%
Q2 2020$1,0000.0%1,0770.0%0.00%
Q1 2020$1,0000.0%1,0770.0%0.00%
Q4 2019$1,0000.0%1,0770.0%0.00%
Q3 2019$1,0001,0770.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$83,313,0005.12%
Defender Capital, LLC. 4,997,870$12,245,0003.92%
Raffles Associates 543,590$1,332,0001.28%
Prescott General Partners LLC 1,851,851$4,537,0000.16%
DCF Advisers, LLC 85,000$208,0000.08%
Long Focus Capital Management, LLC 215,000$527,0000.07%
Beirne Wealth Consulting Services, LLC 45,000$110,0000.06%
DAFNA Capital Management LLC 80,000$196,0000.05%
Strategic Wealth Investment Group, LLC 65,069$159,0000.04%
Fort Sheridan Advisors LLC 52,931$130,0000.04%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders